A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396574 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

566

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to strategic business decision

Conditions

Migraine

Interventions

DRUG: Lasmiditan

Sponsor

Eli Lilly and Company